Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.51 |
| ▸ | NPC1 | O15118 | 6/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18780592 | 0.98 | RAB9A (0.53) | RAB9ANPC1HPGDMAPTUSP2 | |
| SCHEMBL2025855 | 0.94 | RAB9A (0.49) | RAB9ANPC1HPGDMAPTUSP2 | |
| SCHEMBL26828140 | 0.83 | ALDH1A1 (0.50) | RAB9AMAPTSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL15438546 | 0.82 | TPSAB1 (0.44) | RAB9ANPC1MAPTUSP2MAPK1 | |
| SCHEMBL8496933 | 0.82 | TDP1 (0.50) | RAB9AMAPTMAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL14567934 | 0.80 | ALDH1A1 (0.48) | RAB9ANPC1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL14446152 | 0.80 | L3MBTL1 (0.66) | RAB9ANPC1HPGDMAPK1SMN1; SMN2 | |
| SCHEMBL2904236 | 0.80 | TPSAB1 (0.49) | RAB9AMAPTSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL2904238 | 0.80 | ALDH1A1 (0.44) | RAB9ANPC1HPGDMAPTMAPK1 | |
| SCHEMBL2904241 | 0.80 | TPSAB1 (0.49) | RAB9AMAPTSMN1; SMN2ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312220-A1 | Oxadiazole Derivatives with Crth2 Receptor Activity | 7TM PHARMA A/S (DK) | 2008-12-18 | — | — | US | disclosed |
| US-20080312220-A1 | Oxadiazole Derivatives with Crth2 Receptor Activity | 7TM PHARMA A/S (DK) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312220-A1 | Oxadiazole Derivatives with Crth2 Receptor Activity | HRH2, HRH1, HRH3 | RAB9A 4342/4885NPC1 4320/4885HPGD 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.